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Abstract
The objective of this study was to describe the epidemiology of COVID-19 in Nigeria with a
view of generating evidence to enhance planning and response strategies. A national surveil-
lance dataset between 27 February and 6 June 2020 was retrospectively analysed, with con-
firmatory testing for COVID-19 done by real-time polymerase chain reaction (RT-PCR).
The primary outcomes were cumulative incidence (CI) and case fatality (CF). A total of 40
926 persons (67% of total 60 839) had complete records of RT-PCR test across 35 states
and the Federal Capital Territory, 12 289 (30.0%) of whom were confirmed COVID-19
cases. Of those confirmed cases, 3467 (28.2%) had complete records of clinical outcome (alive
or dead), 342 (9.9%) of which died. The overall CI and CF were 5.6 per 100 000 population
and 2.8%, respectively. The highest proportion of COVID-19 cases and deaths were recorded
in persons aged 31–40 years (25.5%) and 61–70 years (26.6%), respectively; and males
accounted for a higher proportion of confirmed cases (65.8%) and deaths (79.0%). Sixty-six
per cent of confirmed COVID-19 cases were asymptomatic at diagnosis. In conclusion, this
paper has provided an insight into the early epidemiology of COVID-19 in Nigeria, which
could be useful for contextualising public health planning.
Introduction
On 31 December 2019, a cluster of cases of pneumonia of
unknown aetiology was detected in Wuhan City, Hubei
Province, China [1]. On 7 January 2020, the Chinese authorities
identified and announced a novel type of coronavirus as the
cause of the disease [2]. On 30 January 2020, the World Health
Organization (WHO) declared the 2019-nCoV outbreak a
Public Health Emergency of International Concern [3] and a
few days later announced the official name of the virus as
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2) and the disease as Coronavirus Disease 2019
(COVID-19) [4]. COVID-19 was declared a pandemic on 11
March 2020 by the WHO.
The first case of COVID-19 in Nigeria was confirmed on 27
February 2020. The case was a 44-year old Italian citizen who
arrived Nigeria through the Murtala Mohammed International
Airport, Lagos, on a flight via Milan, Italy [5]. This index case
led to the activation of COVID-19 Public Health Emergency
Operation Centers (PHEOC) at national and sub-national levels,
with associated active case finding via contact tracing. By 9
March 2020, 217 contacts were linked to this index case [5], out
of which 136 (63.0%) were under follow-up, with one contact
confirmed positive [6]. The 14-day follow-up for contacts of the
index case ended on 12 March 2020. During this period, two add-
itional unlinked cases were reported in Nigeria. In addition, 42
suspected cases were identified across seven states in Nigeria
namely the Federal Capital Territory (FCT), Edo, Kano, Lagos,
Ogun, Rivers and Yobe [5].
Since the confirmation of the first COVID-19 case in Nigeria,
cases and deaths have risen steadily in the country, although the
government has implemented public health interventions – e.g.
advocacy for physical distancing, complete and partial lockdown,
and ban on large public gatherings including at churches and
mosques – to contain or mitigate spread. As of 6 June 2020, 35
(out of 36) states, plus the FCT, have reported at least one con-
firmed COVID-19 case. A descriptive analysis of the clinical char-
acteristics, treatment modalities and outcomes of the first 32
COVID-19 patients admitted to Mainland Hospital in Lagos
State, Nigeria, found that two-thirds of patients were male, and
the mean age was 38.1 years [7]. This early analysis however is
insufficient to provide a national overview of COVID-19 epidemi-
ology in Nigeria. The Nigeria Centre for Disease Control (NCDC)
coordinates the public health response to COVID-19 in the coun-
try. Through NCDC’s surveillance and laboratory network as well
as coordination of state PHEOCs, epidemiological information on
COVID-19 cases are captured into a real-time networked plat-
form called Surveillance Outbreak Response Management and
Analysis System (SORMAS). This forms the basis for the release
of daily situation reports for COVID-19 on NCDC COVID-19
microsite [8]. By 6 June, thousands of individual records with
laboratory diagnosis contained on SORMAS offered opportunities
to expand and explore country-specific epidemiologic and clinical
characteristics of COVID-19 from the onset of the outbreak. This
study aims to provide the initial descriptive epidemiology of
COVID-19 in Nigeria, with emphasis on the disease magnitude
and patterns in terms of person, place and time.
Methods
Study design, period and settings
We conducted a retrospective analysis of Nigeria surveillance data
between 27 February and 6 June 2020. Nigeria is administratively
divided into 36 states plus the FCT, which are zoned across six
geopolitical areas: South-South; South-West; South-East; North-
East; North-West and North-Central. During the study period,
36 states plus FCT had reported confirmed COVID-19 cases; all
states were actively monitoring for cases through the Integrated
Disease Surveillance and Response system (IDSR) system [9].
Data source
SORMAS, an open-source real-time electronic health surveillance
database, was the primary data source for this study. In 2017,
NCDC adopted SORMAS as its primary digital surveillance plat-
form for implementing the IDSR system [9], and customised it
for the surveillance of priority diseases of public health import-
ance in Nigeria. As part of the country’s preparedness activities,
a COVID-19 module was developed and added to SORMAS in
January 2020. All the surveillance data generated through
SORMAS is owned by NCDC, processed and stored in a central
server at the NCDC headquarters in Abuja, Nigeria.
Study population and data collection
The study population was persons investigated for SARS-CoV-2
infection and captured on SORMAS during the study period.
Samples were collected from suspect cases in line with the
NCDC case definitions (which were in turn derived from WHO
case definitions) in Table 1 [10]. However, these guidelines were
not strictly adhered to as samples were also collected from
some asymptomatic cases and contacts of cases. Trained health-
care personnel (and rapid response team members) investigated
suspected COVID-19 cases, completed a detailed case investiga-
tion form (CIF) and collected a minimum of one nasopharyngeal
or nasal swab, and one oropharyngeal swab using synthetic fibre
swabs with plastic shafts. Collected specimens were triple-
packaged and aseptically transported in viral transport media,
under appropriate temperature conditions (2–4 °C) to a desig-
nated NCDC-certified laboratory in the country, usually based
on proximity. Laboratory diagnosis of COVID-19 was done by
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Table 1. Definition of key study variables
Variable Variable definition and classification
Sociodemographic and clinical variables
Suspect casea Symptoms with international travel: Any person with acute respiratory illness (fever and either cough,
difficulty breathing or shortness of breath) OR new respiratory symptoms without fever (cough, difficulty
breathing or shortness of breath) and no other explanation, AND a history of travel to or residence in a
country reporting COVID-19 within 14 days prior to symptom onset;
OR
Symptoms with contact to confirmed case: Any person with new respiratory symptoms (cough, difficulty
breathing or shortness of breath, with or without fever), AND had contact with a confirmed or probable
COVID-19 case (see definition of contact) in the last 14 days prior to symptom onset;
OR
Acute respiratory illness in an area of moderate or high COVID-19 prevalence with no other explanation: Any
patient with acute respiratory illness within the last 10 days (fever and either cough, difficulty breathing or
shortness of breath); AND in absence of an alternative diagnosis that explains the clinical presentation AND
residing or working in the last 14 days in an area identified by NCDC as a moderate or high prevalence region.
Probable case Any individual who met the criteria for a suspect case and for whom testing for COVID-19 was inconclusive or
for whom testing was positive on a pan-coronavirus assay or where samples were not collected before the
demise of a suspect case.
Confirmed case Any individual with laboratory confirmation of SARS-CoV-2 infection with or without signs and symptoms.
Non-case A non-case was defined as an individual whose RT-PCR test was negative for SARS-CoV-2.
Contactb Any individual who had contact (within 1 m for at least 15 min) with a confirmed case during their
symptomatic period, including one day before symptom onset.
Clinical outcome Clinical outcome was classified as a binary variable: survivor and death. A survivor was a COVID-19 case who
was officially discharged after two consecutive negative tests for SARS-CoV-2; however, one negative test as
discharge criterion was implemented on 2 May 2020.
Sex Sex was defined as either male or female.
Age Age, in years, was based on self-reports by a person or a relative, and was treated both as continuous and
categorical variables, depending on the study priority. As a categorical variable, age was classified on the
basis of clinical and public health relevance as well as for ease of interpretation: 0–4; 5–13; 14–20; 21–30; 31–
40; 41–50; 51–60; 61–70; 71–80; >80.
Residential settingc Residential setting of each person tested for COVID-19 was based on the population size and administrative/
legal criteria for the reporting Local Government Areas (LGA) as recorded by field staff, in line with common
classification of urban and rural classification in Nigeria [12]. For example, an LGA was classified as urban if
‘any one’ of the following criteria was met: (1) State capital; (2) an estimated population size of ⩾20 000; (3)
>75% of its population is engaged in non-agricultural occupations; (4) availability of infrastructure, good
transportation system and a broad array of economic, social and recreational activities.
Health facility Health facility refers to the type of facility each person tested for COVID-19 visited prior to diagnosis or was
identified for diagnosis. Because it was listed on SORMAS without specific categorisation into health facility
type, we utilised the Nigeria Health Facility Registry (HFR) of the Federal Ministry of Health [13] to identify
each health facility type so as to minimise misclassification errors. The HFR has details of all the registered
health facilities in Nigeria including the State, LGA, facility level (primary, secondary and tertiary) and
ownership type (private and public). Overall, each health facility was defined either as primary, secondary, or
tertiary facility; health facilities that could not be identified in the registry were treated as unknown.
Education completed Classified as a categorical variable in line with the Nigerian educational system: No formal education; nursery/
primary; secondary and tertiary/post-secondary. However, given the peculiar nature of the Almajiranci/
Quranic educational system in Nigeria, they were classified under a separate category termed ‘alternative’
education.
Current occupation Classified as a categorical variable as follows: Pupil/student; child; housewife; trader/business; health
professional (e.g. nurse, clinician, laboratorian etc.); animal-related work (e.g. butcher and hunter); farmer;
religious/traditional leaders; transporter and other.
Travel history Classified as local, international and no travel in the last 14 days prior to diagnosis.
Clinical signs and symptoms Defined relative to 14 days before sample collection and classified as binary: yes/no. Examples of clinical
variables include fever (defined as an axillary temperature of 37.5 °C or higher), cough, difficulty breathing,
diarrhoea, headache among others.
Quarantine location Defined as a binary variable: formal institution (e.g. health facility) and informal institution (e.g. home).
Time variables (in days)d
Time from symptom onset to diagnosis Defined as the time difference between the dates of sample collection and self-reported symptom onset
among symptomatic COVID-19 cases only.
(Continued )
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real-time polymerase chain reaction (RT-PCR) in accordance
with the WHO interim guidelines [11]. In addition to clinical
samples, information on patients’ sociodemographic characteris-
tics, signs and symptoms in the 14 days prior to diagnosis, labora-
tory findings and clinical outcome as detailed in the national CIF
was captured on SORMAS. Surveillance and laboratory data were
submitted by trained data collectors (i.e. healthcare personnel) in
real time to the NCDC through the SORMAS platform (config-
ured on mobile devices (e.g. tablets and smartphones) and
laptops) by each reporting State Epidemiologist and testing
laboratory, respectively. All laboratory-confirmed COVID-19
cases were managed according to the NCDC case management
protocol [10], while adherence to infection prevention and control
measures for both health workers and patient was ensured.
Testing for COVID-19 during this study period is free of charge
in Nigeria.
Data management and definition of study variables
De-identified data were retrieved from SORMAS. COVID-19 clas-
sifications (suspect, probable and confirmed case) were entered by
trained data collectors as per the NCDC case definitions [10].
Data management and definitions of key study variables are pre-
sented in Table 1. The missing indicator approach was used to
address missing data.
Definition of outcome variables
The primary outcome variables for this study were cumulative
incidence (CI) and case fatality (CF). CI was defined as the
ratio of COVID-19 cases in a defined area to the estimated popu-
lation of that area. Based on a national average growth rate of
3.2%, CI for each reporting state was calculated using the pro-
jected Nigerian population of 2020 from the 2006 national census
and was multiplied by 100 000 for ease of interpretation. CF was
defined as the proportion of persons diagnosed with COVID-19
who died during the study period, expressed as a percentage
(%). Both CI and CF were calculated for Nigeria and for each
state separately.
Statistical analyses
Binary/categorical variables were described using frequencies and
percentages (%), normally distributed continuous variables by
means and standard deviations (S.D.), and non-normally distribu-
ted continuous variables by medians and interquartile ranges
(IQR). Pearson χ2 test was used to assess how the sociodemo-
graphic and clinical characteristics between COVID-19 cases
(confirmed cases vs. non-cases) and clinical outcome (alive vs.
dead). A P-value of <0.05 was considered statistically significant.
All statistical analyses were carried out in STATA version 13 (Stata
Corp. LP, College Station, TX, United States of America). The
report of this study was structured in accordance with the
STROBE statement.
Ethics
The study protocol was approved by the Nigeria National Health
Research Ethics Committee (NHREC/01/01/2007-22/06/2020).
Results
Characteristics of the study population in relation to COVID-19
infection
Between 27 February and 6 June 2020, 60 839 records were entered
in the COVID-19 SORMAS database in Nigeria, these were classi-
fied as follows: 18 790 suspected cases (30.9%), 73 probable cases
(0.1%), 12 289 confirmed cases (20.2%), 28 637 non-cases
(47.1%) and 1050 non-classified cases (1.7%). This study focuses
on individuals with definitive diagnostic classification (40 926):
confirmed cases (n = 12 289) and non-cases (n = 28 637). The
daily incidence of cases is shown in the epicurve in Figure 1.
Males (65.8%) constituted a higher proportion of confirmed
COVID-19 cases than females (31.6%) (Fig. 2). The mean (S.D.)
age of confirmed COVID-19 cases was 37.1 (15.7) years, with
the highest proportion of these cases recorded among persons
aged 31–40 years (25.5%) and 21–30 years (21.0%) (Table 2).
Despite the high proportion of confirmed cases with missing infor-
mation on education (53.1%), 30.6% reported completing tertiary
Table 1. (Continued.)
Variable Variable definition and classification
Duration in quarantine Defined as the time difference between the end and start dates of quarantine; it was treated as a continuous
variable.
Time to hospitalisation Defined as the time difference between the date of hospital visit or admission and date when laboratory result
was ready; it was treated as a continuous variable.
Duration of hospitalisation Defined as the time difference between the dates of discharge/transfer and visit/admission to hospital; it was
treated as a continuous variable.
Time to death from diagnosis Defined as the time difference between the dates of death and sample collection for laboratory diagnosis of
COVID-19; it was treated as a continuous variable.
Time from sample collection to arrival in
the laboratory
Defined as the time difference between the dates of sample arrival in the laboratory and sample collection; it
was treated as a continuous variable.
Total diagnostic turnaround time Defined as the time difference between sample collection and the date diagnostic test was ready (including
sample collection, transportation, collection and diagnosis at the laboratory); it was also treated as a
continuous variable.
aInitially, some of the returnees from abroad were tested for COVID-19 even in the absence of symptoms.
bFor confirmed asymptomatic cases, period of contact was measured as the 2 days before, through the 14 days after the date on which the sample was taken which led to confirmation; for
symptomatic cases, it was presumably 2 days before symptom onset through 14 days after.
cFor more information on the criteria for urban/rural classification in Nigeria, see [12].
dAll negative values following the subtraction of date variables were dropped.
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education, followed by secondary school certificate holders at
8.6%. For confirmed cases with occupation information available,
9.3% were healthcare workers, while pupil/students and traders
accounted for 6.7% each. The proportion of confirmed cases who
reported history of travel 14 days prior to diagnosis was generally
low, with local and international travels at 4.3% and 1.6%, respect-
ively. Sixty-six per cent (8150/12 289) of confirmed COVID-19
cases were asymptomatic in the 14 days prior to diagnosis.
Among confirmed COVID-19 cases with symptoms (n = 4139;
33.7%), fever (56.4%) and cough (55.5%) were the most common
signs and symptoms reported. Other symptoms commonly
reported among confirmed COVID-19 cases were runny nose
(23.8%), sore throat (19.8%), difficulty in breathing (18.6%), head-
ache (14.1%), diarrhoea (7.9%), nausea (7.5%), vomiting (5.5%)
Fig. 2. Distribution of non-cases and confirmed cases of COVID-19 by age and sex in Nigeria, 26 February to 6 June 2020.
Fig. 1. Suspected COVID-19 cases in Nigeria by case status and date, 26 February to 5 June 2020.
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(n = 28 637 (%)a)
Confirmed case
(n = 12 289 (%))
Total case
(n = 40 926 (%))
Sociodemographic variables
Mean (S.D.) age, yearsb 35.0 (14.8) 37.1 (15.7) 35.6 (15.1)
Age group, years
0–4 624 (2.2) 205 (1.7) 829 (2.0)
5–13 1225 (4.3) 482 (3.9) 1707 (4.2)
14–20 1885 (6.6) 752 (6.1) 2637 (6.4)
21–30 7397 (25.8) 2579 (21.0) 9976 (24.4)
31–40 8106 (28.3) 3128 (25.5) 11 234 (27.5)
41–50 4448 (15.5) 2114 (17.2) 6562 (16.0)
51–60 2634 (9.2) 1301 (10.6) 3935 (9.6)
61–70 963 (3.4) 602 (4.9) 1565 (3.8)
71–80 312 (1.1) 203 (1.7) 515 (1.3)
>80 114 (0.4) 71 (0.6) 185 (0.5)
Missing 929 (3.2) 852 (6.9) 1781 (4.4)‡
Sex
Female 10 136 (35.4) 3880 (31.6) 14 016 (34.3)
Male 18 074 (63.1) 8086 (65.8) 26 160 (63.9)
Missing 427 (1.5) 323 (2.6) 750 (1.8)‡
Residential setting
Rural 2664 (9.3) 719 (5.9) 3383 (8.3)
Urban 11 760 (41.1) 4786 (39.0) 16 546 (40.4)
Unknown 38 (0.1) 26 (0.2) 64 (0.2)
Missing 14 175 (49.5) 6758 (55.0) 20 933 (51.2)‡
Health facility
Primary 2090 (7.3) 1087 (8.9) 3177 (7.8)
Secondary 1177 (4.1) 552 (4.5) 1729 (4.2)
Tertiary 1517 (5.3) 1206 (9.8) 2723 (6.7)
Missing 23 853 (83.3) 9444 (76.9) 33 297 (81.4)‡
Formal education completed
None 563 (2.0) 194 (1.6) 757 (1.9)
Nursery/primary 936 (3.3) 276 (2.3) 1212 (3.0)
Secondary 2568 (9.0) 1057 (8.6) 3625 (8.9)
Tertiary 9719 (33.9) 3759 (30.6) 13 478 (32.9)
Alternative (e.g. Almajiranci) 730 (2.6) 482 (3.9) 1212 (3.0)
Missing 14 121 (49.3) 6521 (53.1) 20 642 (50.4)‡
Current occupation
Pupil/student 2069 (7.2) 683 (5.6) 2752 (6.7)
Child 295 (1.0) 116 (0.9) 411 (1.0)
Housewife 382 (1.3) 150 (1.2) 532 (1.3)
Trader/business 1824 (6.4) 698 (5.7) 2522 (6.2)
Health worker 3544 (12.4) 1139 (9.3) 4683 (11.4)
(Continued )




(n = 28 637 (%)a)
Confirmed case
(n = 12 289 (%))
Total case
(n = 40 926 (%))
Animal-related work 57 (0.2) 24 (0.2) 81 (0.2)
Farmer 468 (1.6) 111 (0.9) 579 (1.4)
Religious/traditional leader 66 (0.2) 32 (0.3) 98 (0.2)
Transporter 160 (0.6) 41 (0.3) 201 (0.5)
Other 11 860 (41.4) 4770 (38.8) 16 630 (40.6)
Missing 7912 (27.6) 4525 (36.8) 12 437 (30.4)‡
Other epidemiological variables
Quarantine location
Formal institution 591 (2.1) 458 (3.7) 1049 (2.6)
Informal institution (home) 3300 (11.5) 1167 (9.5) 4467 (10.9)
Missing 24 746 (86.4) 10 664 (86.8) 35 410 (86.5)‡
Travel history in last 14 days
None 25 882 (90.4) 11 507 (93.6) 37 389 (91.4)
Local 1530 (5.3) 523 (4.3) 2053 (5.0)
International 1071 (3.7) 191 (1.6) 1262 (3.1)
Missing 154 (0.5) 68 (0.6) 222 (0.5)‡
Clinical signs and symptoms among symptomatic persons onlyc
Mean (S.D.) temperature, °C 36.9 (1.1) 37.4 (1.0) 37.0 (1.1)
Abdominal pain
No 8978 (96.5) 4000 (96.6) 12 978 (96.5)
Yes 103 (1.1) 31 (0.8) 134 (1.0)
Missing 226 (2.4) 108 (2.6) 334 (2.5)†
Chest pain
No 8782 (94.4) 3876 (93.7) 12 658 (94.1)
Yes 309 (3.3) 160 (3.8) 469 (3.5)
Missing 216 (2.3) 103 (2.5) 319 (2.4)‡
Chills/sweat
No 8981 (96.5) 3973 (96.0) 12 954 (96.3)
Yes 104 (1.1) 63 (1.5) 167 (1.2)
Missing 222 (2.4) 103 (2.5) 325 (2.4)‡
Confusion
No 9036 (97.1) 3990 (96.4) 13 026 (96.9)
Yes 29 (0.3) 14 (0.3) 43 (0.3)
Missing 242 (2.6) 135 (3.3) 377 (2.8)‡
Cough
No 4355 (46.8) 1816 (43.9) 6171 (45.9)
Yes 4865 (52.3) 2298 (55.5) 7163 (53.3)
Missing 87 (0.9) 25 (0.6) 112 (0.8)‡
Diarrhoea
No 8316 (89.4) 3731 (90.1) 12 047 (89.6)
Yes 815 (8.8) 327 (7.9) 1142 (8.5)
Missing 176 (1.9) 81 (2.0) 257 (1.9)‡
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(n = 28 637 (%)a)
Confirmed case
(n = 12 289 (%))
Total case
(n = 40 926 (%))
Difficulty in breathing
No 7231 (77.7) 3280 (79.3) 10 511 (78.2)
Yes 1892 (20.3) 768 (18.6) 2660 (19.8)
Missing 184 (2.0) 91 (2.2) 275 (2.1)‡
Fatigue
No 8792 (94.5) 3816 (92.2) 12 608 (93.8)
Yes 294 (3.2) 216 (5.2) 510 (3.8)
Missing 221 (2.4) 107 (2.6) 328 (2.4)‡
Fever
No 5314 (57.1) 1775 (42.9) 7089 (52.7)
Yes 3941 (42.3) 2334 (56.4) 6275 (46.7)
Missing 52 (0.6) 30 (0.7) 82 (0.6)‡
Headache
No 8283 (89.0) 3475 (84.0) 11 758 (87.5)
Yes 808 (8.7) 583 (14.1) 1391 (10.4)
Missing 216 (2.3) 81 (1.9) 297 (2.2)‡
Joint pain
No 8975 (96.4) 3975 (96.0) 12 950 (96.3)
Yes 104 (1.1) 54 (1.3) 158 (1.2)
Missing 228 (2.5) 110 (2.7) 338 (2.5)‡
Malaise
No 5588 (60.0) 1920 (46.4) 7508 (55.8)
Yes 100 (1.1) 92 (2.2) 192 (1.4)
Missing 3619 (38.9) 2127 (51.4) 5746 (42.7)‡
Muscle pain
No 8842 (95.0) 3936 (95.1) 12 778 (95.0)
Yes 231 (2.5) 96 (2.3) 327 (2.4)
Missing 234 (2.5) 107 (2.6) 341 (2.5)‡
Nausea
No 8393 (90.2) 3736 (90.3) 12 129 (90.2)
Yes 729 (7.8) 311 (7.5) 1040 (7.7)
Missing 185 (2.0) 92 (2.2) 277 (2.1)‡
Pharyngeal exudate
No 5638 (60.6) 1996 (48.2) 7634 (56.8)
Yes 9 (0.1) 3 (0.1) 12 (0.1)
Missing 3660 (39.3) 2140 (51.7) 5800 (43.1)‡
Rapid breathing
No 7467 (80.2) 2932 (70.8) 10 399 (77.3)
Yes 115 (1.2) 61 (1.5) 176 (1.3)
Missing 1725 (18.5) 1146 (27.7) 2871 (21.4)‡
Runny nose
No 6776 (72.8) 3067 (74.1) 9843 (73.2)
(Continued )
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and fatigue (5.2%); other symptoms were less than 5.0% including
loss of smell (4.1%) and loss of taste (3.1%).
Characteristics of the study population in relation to clinical
outcome among confirmed COVID-19 cases
Overall, 3467 out of 12 289 confirmed COVID-19 cases had com-
plete records on clinical outcome over the period covered by this
study: 3125 surviving vs. 342 dead (Table 3). Mean age of persons
who died from COVID-19 was 55.5 (16.4) years. Overall, death
from COVID-19 infection increased with increasing age, reaching
its highest proportion at 26.6% among persons aged 61–70 years.
More deaths were among males (79.0%) than females (19.9%), simi-
lar to the gender distribution of COVID-19 cases. Regarding the
occupation of those who died, 7.3% of death was recorded among
traders, while 40.6% had missing data. Among those who died
from COVID-19, 62.0% (212/342) had shown at least one clinical
symptom in the 14 days prior to diagnosis (results not shown in
Table 3). Of these, cough (72.6%), fever (64.6%) and difficulty in
breathing (51.4%) were the most commonly recorded signs and
symptoms. Other common symptoms recorded at diagnosis were
sore throat (16.5%), runny nose (15.1) and vomiting (12.3%).
Description of clinical time variables
Table 4 describes the timelines for clinical variables from available
records during this study period. Based on the records of 8370
confirmed COVID-19 cases, the median (IQR) turnaround time
for laboratory diagnosis was 2 (1–4) days, whereas it was 1 (1–
3) day among 17 817 non-cases. Median (IQR) time from self-
reported onset of symptom to sample collection for laboratory
diagnosis among 2426 confirmed COVID-19 cases with symptom
presentation was 7 (2–17) days. Among 186 deaths from
COVID-19 infection, the median (IQR) time from sample collec-
tion for laboratory diagnosis to death was 4 (1–8) days.
Cumulative incidence of COVID-19 and case fatality in Nigeria,
27 February–6 June 2020
The overall CI of COVID-19 infection and CF in Nigeria during the
study period was 5.6 per 100 000 population and 2.8%, respectively
(Table 5). Lagos State (39.9 per 100 000), followed by the FCT (19.4
per 100 000), recorded the highest CI in Nigeria during this study
period. Other States with CI higher than the national figure include
Edo (8.6 per 100 000), Kano (6.8 per 100 000), Ogun (5.9 per 100




(n = 28 637 (%)a)
Confirmed case
(n = 12 289 (%))
Total case
(n = 40 926 (%))
Yes 2377 (25.5) 986 (23.8) 3363 (25.0)
Missing 154 (1.7) 86 (2.1) 240 (1.8)‡
Sore throat
No 6562 (70.5) 3276 (79.1) 9838 (73.2)
Yes 2590 (27.8) 818 (19.8) 3408 (25.3)
Missing 155 (1.7) 45 (1.1) 200 (1.5)‡
Vomiting
No 8552 (91.9) 3823 (92.4) 12 375 (92.0)
Yes 577 (6.2) 228 (5.5) 805 (6.0)
Missing 178 (1.9) 88 (2.1) 266 (2.0)‡
Loss of smell
No 5204 (55.9) 2926 (70.7) 8130 (60.4)
Yes 43 (0.5) 170 (4.1) 213 (1.6)
Missing 4060 (43.6) 1043 (25.2) 5103 (38.0)‡
Loss of taste
No 5200 (55.9) 2966 (71.7) 8166 (60.7)
Yes 49 (0.5) 130 (3.1) 179 (1.3)
Missing 4058 (43.6) 1043 (25.2) 5101 (38.0)‡
Conjunctival injection
No 9058 (97.3) 4017 (97.1) 13 075 (97.2)
Yes 17 (0.2) 13 (0.3) 30 (0.2)
Missing 232 (2.5) 109 (2.6) 341 (2.5)‡
aPercentages in some instances may be greater than 100.0% due to rounding up.
bBased on 39 145 observations.
cAnalyses were restricted to individuals who showed symptoms during the study period: non-cases (9307), confirmed cases (4139) and total cases (13 446).
†P-value <0.05.
‡P-value <0.001.
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Table 3. Distribution of sociodemographic and clinical characteristics of the
study population in relation to clinical outcome from COVID-19 infection
Variable








(n = 3467 (%))
Sociodemographic characteristics
Mean (S.D.) age, years 35.6 (15.3) 55.5 (16.4) 37.1 (15.7)Φ
Age group, years
0–4 32 (1.0) 1 (0.3) 33 (0.9)
5–13 185 (5.9) 1 (0.3) 186 (5.4)
14–20 291 (9.3) 6 (1.8) 297 (8.6)
21–30 646 (20.7) 24 (7.0) 670 (19.3)
31–40 809 (25.9) 30 (8.8) 839 (24.2)
41–50 534 (17.1) 47 (13.7) 581 (16.8)
51–60 346 (11.1) 81 (23.7) 427 (12.3)
61–70 121 (3.9) 91 (26.6) 212 (6.1)
71–80 37 (1.2) 36 (10.5) 73 (2.1)
>80 12 (0.4) 11 (3.2) 23 (0.7)
Missing 112 (3.6) 14 (4.1) 126 (3.6)‡
Sex
Female 925 (29.6) 68 (19.9) 993 (28.6)
Male 2188 (70.0) 270 (79.0) 2458 (70.9)
Missing 12 (0.4) 4 (1.1) 16 (0.5)‡
Residential setting
Rural 244 (7.8) 22 (6.4) 266 (7.7)
Urban 1357 (43.4) 157 (45.9) 1514 (43.7)
Unknown 4 (0.1) 0 (0.0) 4 (0.1)
Missing 1520 (48.6) 163 (47.7) 1683 (48.5)NS
Health facility
Primary 275 (8.8) 5 (1.5) 280 (8.1)
Secondary 186 (6.0) 22 (6.4) 208 (6.0)
Tertiary 274 (8.8) 43 (12.6) 317 (9.1)
Missing 2390 (76.5) 272 (79.5) 2662 (76.8)‡
Formal education completed
None 124 (4.0) 8 (2.3) 132 (3.8)
Nursery/primary 94 (3.0) 6 (1.8) 100 (2.9)
Secondary 306 (9.8) 30 (8.8) 336 (9.7)
Tertiary 1072 (34.3) 102 (29.8) 1174 (33.9)
Alternative (e.g.
Almajiranci)
100 (3.2) 11 (3.2) 111 (3.2)
Missing 1429 (45.7) 185 (54.1) 1614 (46.6)NS
Current occupation
Pupil/student 209 (6.7) 3 (0.9) 212 (6.1)
Child 38 (1.2) 0 (0.0) 38 (1.1)












(n = 3467 (%))
Trader/business 212 (6.8) 25 (7.3) 237 (6.8)
Health worker 343 (11.0) 12 (3.5) 355 (10.2)
Animal-related work 6 (0.2) 0 (0.0) 6 (0.2)
Farmer 40 (1.3) 14 (4.1) 54 (1.6)
Religious/traditional
leader
12 (0.4) 4 (1.2) 16 (0.5)
Transporter 12 (0.4) 2 (0.6) 14 (0.4)
Other 1193 (38.2) 135 (39.5) 1328 (38.9)
Missing 1001 (32.0) 139 (40.6) 1140 (32.9)‡
Other epidemiological variables
Quarantine location
Formal institution 299 (9.6) 27 (7.9) 326 (9.4)
Home 464 (14.9) 48 (14.0) 512 (14.8)
Missing 2362 (75.6) 267 (78.1) 2629 (75.8)NS
Travel history in last 14 days
None 2696 (86.3) 317 (92.7) 3013 (86.9)
Local 284 (9.1) 16 (4.7) 300 (8.7)
International 108 (3.5) 4 (1.2) 112 (3.2)
Missing 37 (1.2) 5 (1.5) 42 (1.2)‡
Clinical signs and symptoms among symptomatic persons onlyc
Mean (S.D.) temperature, °Cd 37.4 (1.0) 37.5 (1.3) 37.4 (1.1)
Abdominal pain
No 1286 (94.1) 198 (93.4) 1484 (94.0)
Yes 14 (1.0) 6 (2.8) 20 (1.3)
Missing 66 (4.8) 8 (3.8) 74 (4.7)‡
Chest pain
No 1251 (91.6) 191 (90.1) 1442 (91.4)
Yes 53 (3.9) 14 (6.6) 67 (4.3)
Missing 62 (4.5) 7 (3.3) 69 (3.4)‡
Chills/sweat
No 1281 (93.8) 201 (94.8) 1482 (93.9)
Yes 26 (1.9) 3 (1.4) 29 (1.8)
Missing 59 (4.3) 8 (3.8) 67 (4.3)‡
Confusion
No 1298 (95.0) 200 (94.3) 1498 (94.9)
Yes 4 (0.3) 4 (1.9) 8 (0.5)
Missing 64 (4.7) 8 (3.8) 72 (4.6)‡
Cough
No 607 (44.4) 55 (25.9) 662 (42.0)
Yes 751 (55.0) 154 (72.6) 905 (57.3)
(Continued )
10 K. O. Elimian et al.
Nigerian States, Ondo recorded the highest figure at 16.7%, followed
by Yobe State (13.5%), Kebbi State (11.4%) and Bayelsa State
(10.0%). The spatial distribution of confirmed COVID-19 cases
and death by state is presented in Figure 3.
Table 3. (Continued.)
Variable








(n = 3467 (%))
Missing 8 (0.6) 3 (1.4) 11 (0.7)‡
Diarrhoea
No 1206 (88.3) 186 (87.7) 1392 (88.2)
Yes 112 (8.2) 20 (9.4) 132 (8.4)
Missing 48 (3.5) 6 (2.8) 54 (3.4)‡
Difficulty in breathing
No 1066 (78.0) 98 (46.2) 1164 (73.8)
Yes 237 (17.4) 109 (51.4) 346 (21.9)
Missing 63 (4.6) 5 (2.4) 68 (4.3)‡
Fatigue
No 1207 (88.4) 182 (85.9) 1389 (88.0)
Yes 93 (6.8) 24 (11.3) 117 (7.4)
Missing 66 (4.8) 6 (2.8) 72 (4.6)‡
Fever
No 498 (36.4) 73 (34.4) 571 (36.1)
Yes 855 (62.6) 137 (64.6) 992 (62.9)
Missing 13 (1.0) 2 (1.0) 15 (1.0)‡
Headache
No 1070 (78.3) 186 (87.7) 1256 (79.6)
Yes 251 (18.4) 20 (9.4) 271 (17.2)
Missing 45 (3.3) 6 (2.8) 51 (3.2)‡
Joint pain
No 1278 (93.6) 199 (93.9) 1477 (93.6)
Yes 22 (1.6) 6 (2.8) 28 (1.8)
Missing 66 (4.8) 7 (3.3) 73 (4.6)‡
Malaise
No 957 (70.1) 102 (48.1) 1059 (67.1)
Yes 60 (4.4) 13 (6.1) 73 (4.6)
Missing 349 (25.6) 97 (45.8) 446 (28.3)‡
Muscle pain
No 1253 (91.7) 199 (93.9) 1452 (92.0)
Yes 49 (3.6) 6 (2.8) 55 (3.5)
Missing 64 (4.7) 7 (3.3) 71 (4.5)‡
Nausea
No 1219 (89.2) 189 (89.2) 1408 (89.2)
Yes 87 (6.4) 16 (7.6) 103 (6.5)
Missing 60 (4.4) 7 (3.3) 67 (4.3)‡
Rapid breathing
No 1040 (76.1) 137 (64.6) 1177 (74.6)
Yes 21 (1.5) 11 (5.2) 32 (2.0)












(n = 3467 (%))
Runny nose
No 1011 (74.0) 174 (82.1) 1185 (75.1)
Yes 297 (21.7) 32 (15.1) 329 (20.9)
Missing 58 (4.3) 6 (2.8) 64 (4.1)‡
Sore throat
No 1052 (77.0) 175 (82.6) 1227 (77.8)
Yes 296 (21.7) 35 (16.5) 331 (21.0)
Missing 18 (1.3) 2 (0.9) 20 (1.2)‡
Vomiting
No 1247 (91.3) 181 (85.4) 1428 (90.5)
Yes 59 (4.3) 26 (12.3) 85 (5.4)
Missing 60 (4.4) 5 (2.4) 65 (4.1)‡
Loss of smell
No 762 (55.8) 135 (63.7) 897 (56.8)
Yes 22 (1.6) 1 (0.5) 23 (1.5)
Missing 582 (42.6) 76 (35.9) 658 (41.7)NS
Loss of taste
No 760 (55.6) 132 (62.3) 892 (56.5)
Yes 25 (1.8) 5 (2.4) 30 (1.9)
Missing 581 (42.5) 75 (35.3) 656 (41.6)NS
Conjunctival injection
No 1294 (94.7) 205 (96.7) 1499 (95.0)
Yes 6 (0.4) 0 (0.0) 6 (0.4)
Missing 66 (4.8) 7 (3.3) 73 (4.6)‡
Pneumonia
No 1289 (94.3) 201 (94.8) 1.490 (94.4)
Yes 1 (0.1) 3 (1.4) 4 (0.3)
Missing 76 (5.6) 8 (3.8) 84 (5.3)‡
ARDS
No 1287 (94.2) 196 (92.5) 1483 (94.0)
Yes 16 (1.2) 10 (4.7) 26 (1.6)
Missing 63 (4.6) 6 (2.8) 69 (4.4)‡
ARDS, acute respiratory distress syndrome.
a8822 persons diagnosed with COVID-19 did not yet have a clinical outcome during the study
period.
bPercentages in some instances may be greater than 100.0% due to rounding up.
cOnly for symptomatic confirmed COVID-19 cases with records of clinical outcome: survivor
(n = 1366), dead (n = 212), and total (n = 1578).
d692 total records were used for the assessment of temperature.
†P-value <0.05; ‡ P-value <0.001; NS = P-value not statistically significant (i.e. >0.05).
Φ: P-value from t-test was <0.0001; mean difference was 19.9 years.
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Discussion
Summary of key findings
We have provided a description of the first national epidemiology
of COVID-19 cases and associated clinical features and outcomes
for Nigeria. There were 12 289 confirmed COVID-19 cases and
28 637 non-cases in 35 states plus the FCT in Nigeria between
27 February and 6 June 2020. During this period, there were
342 deaths, a CI of 5.6 per 100 000 and a CF of 2.8% overall.
Interpretation of key findings
After South Africa, Nigeria is the second most-affected African
country in terms of recorded confirmed COVID-19 cases and
death as of 7 June 2020 [14]. However, the CI of COVID-19 in
Nigeria during the study period, at 5.6 per 100 000 population,
is substantially lower than in some non-African countries at a
similar stage in their epidemic. For example, about three months
after the first confirmed case in the United States, CI was 119⋅6
per 100 000 population, far more than that of Nigeria’s; with
Minnesota, the State with the lowest CI, having a CI of 20.6 per
100 000 population [15]. Additionally, many European countries
reached a CI of at least 4.0 confirmed cases per 100 000 popula-
tion over a period of less than 1 month [16]. A possible reason
for lower CI in Nigeria could be due to a relatively low testing cap-
acity in the country as compared to the US and European
countries.
There was substantial variability in COVID-19 incidence
among the states in Nigeria. The heterogeneity in CIs within
Nigeria could be attributable, in part, to international travels as
indicated by the figures recorded by Lagos State (39.9 per 100
000) and the FCT (19.4 per 100 000) with the two major inter-
national airports in the country. Another possible explanation
might be due to variations in the estimated population of states
in Nigeria, with smaller population recording a higher CI and
vice-versa. For example, Ekiti State (3 655 663 population) and
Enugu State (4 926 955 population) each recorded 29 confirmed
COVID-19 cases during this study period; but the latter recorded
a lower CI (0.6 per 100 000 population) than the former (0.8 per
100 000). Moreover, all the Nigerian states did not have a similar
testing capacity during the study period, and this might have con-
tributed to the observed findings in terms of the numerator fig-
ures for calculating CIs. Similarly, the CF of 2.8% in this study
is lower than several other countries which have been hard hit
by the COVID-19 pandemic. There is a wide range of CFs
among non-African countries (from 0.1% in Singapore to
16.2% in Belgium [17]) and in African countries (from 0.0% in
Uganda to 8.2% in Chad) during this study period [14].
Nigeria’s observed CF of 2.8% is on the lower end of the range
reported outside and within Africa, but higher than the 2.4%
(3210 deaths/133 119 confirmed cases) recorded for the entire
Africa as of 7 June 2020 [14]. The variation in CF in Nigeria
could be an indication of varying health system capacity and pre-
paredness across the country. An unpublished study indicates that
Lagos State – with the highest CI but a CF of 1.3% – invested sub-
stantially in case management of COVID-19 patients as part of its
preparedness activities. The overall CF in Nigeria could be partly
due to its much younger population compared to the United
States and most countries in Europe [18]; similar trends in deaths
by age from COVID-19 have been reported in China [19]. Just as
cases are potentially underestimated due to inadequate testing, it
is likely that deaths from COVID-19 are also underestimated,
especially in places like Kano, which reported significant increases
in deaths in April [20].
In contrast to deaths from COVID-19, a higher proportion of
COVID-19 cases was recorded among economically active age
groups, suggesting potential role of socio-economic or work-
related activities rather than immunological capacity. Children
under 5 years of age and those aged 5–13 years, respectively,
accounted for 1.7% and 3.9% of confirmed COVID-19 cases in
this study. These findings are comparable to those from a recent
global systematic review [21]. Although it remains unclear why
children are less affected by COVID-19 than older individuals,
evidence suggests differences in immune system function [22].
The higher infection rate among males in this study corresponds
to evidence reported in the WHO African region, where males in
the 31–39 and 40–49 age groups accounted for 62% of 5178
recorded cases [14]. Outside Africa, early findings of the clinical
characteristics of 41 confirmed COVID-19 cases in Wuhan,
China, reported males to have accounted for 30 (73.0%) of the
cases [23]. A study in Italy also reported male preponderance
[24]. A combination of genetic and physiological factors has
been hypothesised as possible explanations for the potential
male bias. For example, the wider distribution of SARS-CoV-2
cellular receptor, angiotensin-converting enzyme 2 (ACE-2), in
male over females has been postulated [25]. In a patriarchal sys-
tem such as seen in Nigeria, men are more likely to engage in eco-
nomic activities outside of the household and potentially become











Time from symptom onset to sample collection for
diagnosis
2426 7 (2–17) 5481 5 (1–12)
Duration in quarantine 259 14 (12–42) 808 14 (2–43)
Duration on admission in hospital 111 19 (9–41) 34 7 (1–61)
Time from sample collection to death 186 4 (1–8) 39 1 (0–28)
Time from sample collection to transportation/
shipment to the laboratory
2541 0 (0–2) 7847 0 (0–1)
Total laboratory turnaround time 8370 2 (1–4) 17 817 1 (1–3)
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more exposed to SARS-CoV-2 infection than women. While this
may be more feasible during a controlled economy, such as that
seen during the suspension of non-essential economic activities
in the early phase of COVID-19 outbreak in Nigeria, it may not
be applicable when socio-economic activities are functional.
This is because women are increasingly partaking in the













Lagos 14 009 120 5587 39.9 72 1.3
FCT 4 880 010 945 19.4 23 2.4
Edo 4 673 229 403 8.6 19 4.7
Kano 14 783 518 999 6.8 47 4.7
Ogun 5 873 430 349 5.9 12 3.4
Gombe 3 658 473 207 5.7 10 4.8
Borno 6 629 190 350 5.3 22 6.3
Oyo 8 929 410 422 4.7 7 1.7
Katsina 8 761 794 397 4.5 20 5.0
Rivers 8 280 753 362 4.4 18 5.0
Jigawa 6 488 878 283 4.4 7 2.5
Ebonyi 3 199 362 135 4.2 0 0.0
Kwara 3 586 485 142 4.0 1 0.7
Kaduna 9 176 219 344 3.7 11 3.2
Bauchi 7 468 016 273 3.7 2 0.7
Nasarawa 2 818 371 78 2.8 4 5.1
Plateau 4 615 698 119 2.6 2 1.7
Delta 6 369 849 155 2.4 8 5.2
Sokoto 5 592 043 129 2.3 14 10.9
Zamfara 5 066 556 77 1.5 5 6.5
Yobe 3 757 947 52 1.4 7 13.5
Bayelsa 2 541 682 30 1.2 3 10.0
Osun 5 320 967 49 0.9 4 8.2
Adamawa 4 727 312 42 0.9 4 9.5
Ondo 5 204 858 42 0.8 7 16.7
Abia 4 115 152 31 0.8 0 0.0
Ekiti 3 655 663 29 0.8 2 6.9
Niger 6 308 295 45 0.7 1 2.2
Akwa-Ibom 6 260 322 45 0.7 2 4.4
Kebbi 4 965 722 35 0.7 4 11.4
Imo 6 115 745 36 0.6 0 0.0
Enugu 4 926 955 29 0.6 1 3.4
Taraba 3 402 844 19 0.6 0 0.0
Anambra 6 155 892 32 0.5 3 9.4
Benue 6 381 985 15 0.2 0 0.0
Kogib 4 959 006 2 0.0 0 0.0
Overallc 217 971 548 12 289 5.6 342 2.8
aExcluding Cross River State with no official report of COVID-19 during the study period.
b0.04 when values were not rounded to one decimal place.
cBased on the 2020 projected Nigerian population.
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workforce in Nigeria, such that the traditional trends of ‘male
breadwinner and female family support’ are fast eroding [26].
The median length of stay of 111 patients with COVID-19 in
hospital in this study was 19 days, which is within the range out-
side of China (4–21 days), but comparatively lower than that from
China (4–53 days) [27]. In general, differences in the length of
hospital stay may be attributable to variations in criteria for
admission and discharge across different countries as well as tim-
ing within the pandemic [27]. Early diagnosis is fundamental for
effective management of COVID-19 cases; thus, a median turn-
around time of 2 (1–4) days for laboratory diagnosis as noted
in the current study seems impressive, and possibly an indication
of ongoing measures being championed by the NCDC to
strengthen molecular diagnostic capacity in Nigeria. However,
we lacked information on when laboratory test was received by
a COVID-19 suspected case, as turnaround time only included
the time from sample collection to availability of result.
The symptomatic status of confirmed COVID-19 cases in this
analysis is noteworthy, as over half of them were asymptomatic at
testing. A scoping review of the literature found that between 5%
and 80% of people testing positive for SARS-CoV-2 may be
asymptomatic [28], placing the 66% in the current study closer
to the maximum range. It is possible that the case investigation
approach adopted during testing might have underestimated
symptoms: patients were initially asked whether they were symp-
tomatic and probed about individual symptoms only if they
answered in the affirmative. Stigma associated with COVID-19
in Nigeria might contribute to people not reporting symptoms
when they get tested [29]. Furthermore, it is possible for asymp-
tomatic status at diagnosis to change in the course of an illness, in
which case such persons could be better classified as pre-
symptomatic cases, so the proportion of truly asymptomatic
cases cannot be described by these data. Nevertheless, this scen-
ario could pose a challenge to community surveillance activities
and implementation of public health interventions (e.g. quaran-
tine and isolation). Thus, the possibility of COVID-19 transmis-
sion by asymptomatic cases in Nigeria needs to be explored and
addressed, both in terms of research and community risk commu-
nication activities.
The most common signs and symptoms among symptomatic
confirmed COVID-19 cases in the 14 days prior to diagnosis
were fever (56.4%) and cough (55.5%). This trend is similar to
that recorded in a recent systematic review of the literature for
China [30]; however, while fatigue was the third most frequently
recorded symptom in China, its frequency was low in our study at
5.2%. Similarly, cough, fever and difficulty in breathing, in that
order, were the most commonly recorded symptoms at diagnosis
among persons who died from COVID-19 infection. The com-
mon occurrence of difficulty in breathing in deceased patients
has been identified as a major driver of adverse clinical outcomes
among COVID-19 patients [31]. Although relatively small in pro-
portion due to late recording during the study period, loss of
smell and loss of taste among confirmed COVID-19 cases in
this study are consistent with available evidence [32]. However,
Fig. 3. (a) Spatial distribution of confirmed COVID-19 cases by Nigerian State, 28 February–6 June 2020. (b) Spatial distribution of confirmed COVID-19 deaths by
Nigerian State, 28 February–6 June 2020.
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being a descriptive study, these data do not have the capacity to
establish a causal association between observed clinical symptoms
and COVID-19 infection or death. Thus, a follow-up study aimed
at exploring these associations is recommended. It is also worth
noting that the fever which is one of the common symptoms
noted in this study is often common in endemic febrile illnesses
in Nigeria including malaria, Lassa fever and yellow fever. As
such, in the case of a co-infection, misclassification of illnesses
is likely if symptoms alone are used for COVID-19 case defini-
tions [33]. The symptomatic and geographic convergence of
COVID-19 and common febrile diseases in Nigeria therefore
requires continuous strengthening of definitive diagnostic
approaches in the country. About 9% of COVID-19 infections
occurred in healthcare workers during this study period.
COVID-19 infection among health workers is of prominent pub-
lic health importance as it could potentially enhance disease
transmission [34] and further weaken a health system that already
struggles with insufficient human resources for health.
Strengths and limitations
This study has provided the first national epidemiological evi-
dence on COVID-19 in Nigeria, necessary for public health plan-
ning and health system strengthening. However, this study is
limited by the substantial proportion of missing data within
some of the sociodemographic (e.g. residential setting and health
facility) and clinical (e.g. malaise, pharyngeal exudate, rapid
breathing, loss of smell and taste) variables studied. The late
addition of loss of smell and taste to the CIF in Nigeria may partly
explain why data recorders were not accustomed to capturing
them. The high proportion of missing data on some key indica-
tors has prompted a systemic effort to improve the quality of
SORMAS data, and a dedicated Data Quality Improvement
Project (DQIP) was initiated in April to improve completeness
of key variables to above 90%.
In conclusion, this study has provided an early insight into the
epidemiology of COVID-19 in Nigeria. Evidence from this study,
such as the high proportion of cases among the active age group
and high proportion of asymptomatic cases at diagnosis, will be
useful for policymakers and stakeholders in the health and
other sectors in contextualising public health planning and
response as well as for scientific activities in the country. Such
measures could include intensifying NPIs at work and commer-
cial places where this age group is mostly found, and adapting
case finding protocols to include routine testing of asymptomatic
contacts of confirmed cases.
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